The Pathology Core Facility of the Robert H. Lurie Comprehensive Cancer Center provides pathological analysis and specimen procurement, processing and distribution services to the NU research community. Pathological analysis in the past was mostly limited to routine tissue processing, staining and a limited panel of immunohistochemical stains. Today, pathological analysis in cancer research involves more sophisticated testing, including high-throughput tissue microarray generation, novel immunohistochemistry, in situ hybridization, or digital imaging analysis for the objective assessment of tissue based assays. Similarly, specimen procurement, processing and distribution are increasingly more sophisticated today. Cancer researchers now require technologies such as DNA/RNA/mRNA extraction, generation of cell monolayers from body fluids, laser capture microdissection, isolation of circulating tumor cells, and other technologies to address cancer-related questions. An exciting development in cancer care in the past few years is the use of targeted therapies and the sub-stratification of patients into more precise treatment groups. Examples include her2/neu testing by FISH or IHC in breast cancer, thymidylate synthase testing in colon cancer, MSI testing in colon cancer, c-kit testing in a variety of tumors, pharmacogenomics and others. Other examples of these """"""""cutting-edge"""""""" approaches to cancer research are presented throughout this grant. The PCF is fortunate to be at the forefront of these exciting developments in cancer care in its capacity as the Reference Laboratory for the Eastern Cooperative Oncology Group. Continued funding of the PCF infrastructure will allow it to continue to meet the growing and increasingly complex needs of cancer patients and cancer researchers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Joyce, Brian T; Zheng, Yinan; Zhang, Zhou et al. (2018) miRNA-Processing Gene Methylation and Cancer Risk. Cancer Epidemiol Biomarkers Prev 27:550-557
Kenney, Grace E; Dassama, Laura M K; Pandelia, Maria-Eirini et al. (2018) The biosynthesis of methanobactin. Science 359:1411-1416
Symes, Yael R; Barrington, Clare; Austin, Jane et al. (2018) Advice to patients undergoing stem cell transplant: Content analysis of survivor peer support narratives. J Health Psychol 23:818-828
Chu, Lan H; Indramohan, Mohanalaxmi; Ratsimandresy, Rojo A et al. (2018) The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat Commun 9:996
Ugolkov, Andrey V; Bondarenko, Gennadiy I; Dubrovskyi, Oleksii et al. (2018) 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs 29:717-724
Lewis, Phillip L; Green, Richard M; Shah, Ramille N (2018) 3D-printed gelatin scaffolds of differing pore geometry modulate hepatocyte function and gene expression. Acta Biomater 69:63-70
Volk, Andrew; Liang, Kaiwei; Suraneni, Praveen et al. (2018) A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell 34:707-723.e7
Chen, Charlotte H; Palmer, Liam C; Stupp, Samuel I (2018) Self-Repair of Structure and Bioactivity in a Supramolecular Nanostructure. Nano Lett 18:6832-6841
Du, Jingshan S; Chen, Peng-Cheng; Meckes, Brian et al. (2018) Windowless Observation of Evaporation-Induced Coarsening of Au-Pt Nanoparticles in Polymer Nanoreactors. J Am Chem Soc 140:7213-7221
Graves, Stephen; Seagle, Brandon-Luke L; Kocherginsky, Masha et al. (2018) Scholarship Support for Veterans Enrolling in MD, JD, and MBA Programs. JAMA 320:1197-1198

Showing the most recent 10 out of 1972 publications